D.E. Shaw & Co
ANAB icon

D.E. Shaw & Co’s AnaptysBio ANAB Stock Holding History

D.E. Shaw & Co’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-23,500
Closed -$2.45M – 3677
2018
Q1 		$2.45M Buy
+23,500
New +$2.65M ﹤0.01% 1919

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

D.E. Shaw & Co's ANAB Position: Q1 2026 in Review

D.E. Shaw & Co reduced its AnaptysBio (ANAB) stake by 14% in Q1 2026, selling an estimated $4.9M and leaving 579,296 shares worth $32.1M. The position accounts for 0.02% of the portfolio, ranked #892.

D.E. Shaw & Co first reported a position in ANAB in Q3 2017 and has held it in 29 quarters since. The position peaked at $32.5M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • D.E. Shaw & Co held 579,296 shares of AnaptysBio worth $32.1M as of Q1 2026.
  • D.E. Shaw & Co sold 90,992 AnaptysBio shares in Q1 2026, an estimated $4.9M.
  • AnaptysBio made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #892 holding.
  • D.E. Shaw & Co first reported a position in AnaptysBio in Q3 2017 and has held it in 29 quarters since.
  • D.E. Shaw & Co's AnaptysBio position peaked at $32.5M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.